AU4347696A
(en)
*
|
1994-12-23 |
1996-07-19 |
Deutsche Om Arzneimittel Gmbh |
Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
|
US8197430B1
(en)
|
1998-05-22 |
2012-06-12 |
Biopheresis Technologies, Inc. |
Method and system to remove cytokine inhibitor in patients
|
US6620382B1
(en)
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
US6379708B1
(en)
*
|
1999-11-20 |
2002-04-30 |
Cytologic, Llc |
Method for enhancing immune responses in mammals
|
ES2747357T3
(es)
*
|
2001-03-14 |
2020-03-10 |
Dako Denmark As |
Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
|
US20040072262A1
(en)
|
2002-10-11 |
2004-04-15 |
Montero-Julian Felix A. |
Methods and systems for detecting MHC class I binding peptides
|
US20040248205A1
(en)
*
|
2003-04-16 |
2004-12-09 |
Stern Lawrence J. |
Major histocompatibility complex (MHC)-peptide arrays
|
JP4839674B2
(ja)
*
|
2004-05-14 |
2011-12-21 |
東レ株式会社 |
標的物質を迅速簡便に検出する方法およびそのための酵素免疫学的キット
|
AU2005242950A1
(en)
*
|
2004-05-14 |
2005-11-24 |
Toray Industries, Inc. |
Method of rapidly and easily detecting target substance and enzymoimmunological kit
|
US7678379B2
(en)
|
2004-06-17 |
2010-03-16 |
Beckman Coulter, Inc. |
Mycobacterium tuberculosis epitopes and methods of use thereof
|
EP1907852A4
(de)
*
|
2005-07-06 |
2011-07-06 |
Jackson H M Found Military Med |
Stabile quantifizierung und nachweis von immunantwortniveaus mit nicht-null hintergrundpeptiden
|
US20070065514A1
(en)
*
|
2005-09-22 |
2007-03-22 |
Howell Mark D |
Method for enhancing immune responses in mammals
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
US20080075690A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Mark Douglas Howell |
Method for enhancing immune responses in mammals
|
EP2361930A3
(de)
|
2007-03-26 |
2011-10-26 |
Dako Denmark A/S |
Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten
|
EP3023436A1
(de)
|
2007-07-03 |
2016-05-25 |
Dako Denmark A/S |
Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
|
WO2009039854A2
(en)
|
2007-09-27 |
2009-04-02 |
Dako Denmark A/S |
Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
|
DK2254592T3
(da)
|
2008-02-28 |
2019-09-09 |
Dako Denmark As |
MHC-multimerer til Borrelia-diagnostik og sygdom
|
US10722562B2
(en)
|
2008-07-23 |
2020-07-28 |
Immudex Aps |
Combinatorial analysis and repair
|
GB0817244D0
(en)
|
2008-09-20 |
2008-10-29 |
Univ Cardiff |
Use of a protein kinase inhibitor to detect immune cells, such as T cells
|
WO2010037402A1
(en)
|
2008-10-02 |
2010-04-08 |
Dako Denmark A/S |
Molecular vaccines for infectious disease
|
US11992518B2
(en)
|
2008-10-02 |
2024-05-28 |
Agilent Technologies, Inc. |
Molecular vaccines for infectious disease
|
EP2352830B1
(de)
|
2008-10-03 |
2019-01-16 |
CuRNA, Inc. |
Behandlung von krankheiten in verbindung mit apolipoprotein a1 durch hemmung eines natürlichen antisense-transkripts gegen apolipoprotein a1
|
MX2011005912A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
|
EP2370579B1
(de)
|
2008-12-04 |
2017-03-29 |
CuRNA, Inc. |
Behandlung von erythropoetin (epo)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen epo
|
KR20110091796A
(ko)
|
2008-12-04 |
2011-08-12 |
오피케이오 큐알엔에이, 엘엘씨 |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
KR101682735B1
(ko)
|
2009-02-12 |
2016-12-06 |
큐알엔에이, 인크. |
뇌 유래된 신경영양성 인자 (bdnf)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (bdnf) 관련된 질환의 치료
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
CA2761152A1
(en)
|
2009-05-06 |
2010-11-11 |
Opko Curna, Llc |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
CA2761142C
(en)
|
2009-05-06 |
2021-06-08 |
Opko Curna, Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
ES2618572T3
(es)
|
2009-05-08 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd
|
KR101749356B1
(ko)
|
2009-05-18 |
2017-07-06 |
큐알엔에이, 인크. |
재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
EP2435571B1
(de)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
KR101801404B1
(ko)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
JP2013500017A
(ja)
|
2009-07-24 |
2013-01-07 |
カッパーアールエヌエー,インコーポレイテッド |
サ−チュイン(sirt)への天然アンチセンス転写物の阻止によるサ−チュイン(sirt)関連疾患の治療
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
JP6189594B2
(ja)
|
2009-08-11 |
2017-08-30 |
クルナ・インコーポレーテッド |
アディポネクチン(adipoq)に対する天然アンチセンス転写物の抑制によるアディポネクチン(adipoq)関連疾患の治療
|
EP2982755B1
(de)
|
2009-08-21 |
2020-10-07 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit c-terminus des hsp70-interagierenden proteins (chip) durch hemmung des natürlichen antisense-transkripts gegen chip
|
EP2470657B1
(de)
|
2009-08-25 |
2019-10-23 |
CuRNA, Inc. |
Behandlung von iqgap ('iq-motiv-haltiges gtpase-aktivierendes protein')-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen iqgap
|
NO2480669T3
(de)
|
2009-09-25 |
2018-04-07 |
|
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
RU2609631C2
(ru)
|
2009-12-23 |
2017-02-02 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг
|
EP2515947B1
(de)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
|
CN102770540B
(zh)
|
2009-12-29 |
2017-06-23 |
库尔纳公司 |
通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
|
KR101838305B1
(ko)
|
2009-12-29 |
2018-03-13 |
큐알엔에이, 인크. |
NRF1(Nuclear Respiratory Factor 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
|
US20120289583A1
(en)
|
2009-12-31 |
2012-11-15 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
CN102906264B
(zh)
|
2010-01-04 |
2017-08-04 |
库尔纳公司 |
通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
KR101838308B1
(ko)
|
2010-02-22 |
2018-03-13 |
큐알엔에이, 인크. |
피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료
|
RU2612884C2
(ru)
|
2010-04-02 |
2017-03-13 |
Курна, Инк. |
Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
|
KR101900962B1
(ko)
|
2010-04-09 |
2018-09-20 |
큐알엔에이, 인크. |
섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료
|
US9089588B2
(en)
|
2010-05-03 |
2015-07-28 |
Curna, Inc. |
Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
RU2620978C2
(ru)
|
2010-05-26 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
PL2585596T3
(pl)
|
2010-06-23 |
2021-06-28 |
Curna, Inc. |
Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA
|
EP2593547B1
(de)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem discs large homolog (dlg) durch hemmung des natürlichen antisense-transkripts an dlg
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療
|
EA029151B1
(ru)
|
2011-09-06 |
2018-02-28 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
|
DK2825648T3
(en)
|
2012-03-15 |
2018-10-15 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATIVE NEUROTROPHIC FACTOR (BDNF) -related DISEASES BY INHIBITATION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|